Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status

PURPOSE: Anti-programmed death 1 (PD-1) antibodies have emerged as frontline treatments for patients with advanced non-small cell lung cancer (NSCLC) on the basis of global Phase III trials. However, current data regarding responses to anti–PD-1 therapy in older patients with NSCLC or those with poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Taichi, Seto, Takashi, Takamori, Shinkichi, Fujishita, Takatoshi, Toyozawa, Ryo, Ito, Kensaku, Yamaguchi, Masafumi, Okamoto, Tatsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982715/
https://www.ncbi.nlm.nih.gov/pubmed/33762828
http://dx.doi.org/10.2147/OTT.S301500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982715/
https://www.ncbi.nlm.nih.gov/pubmed/33762828
http://dx.doi.org/10.2147/OTT.S301500

Ejemplares similares